This article digs into a new class-action lawsuit out of Connecticut. Boehringer Ingelheim stands accused of hiding cancer risks tied to Zantac and its generic, ranitidine.
Filed in Connecticut Superior Court, the case brings together 95 plaintiffs. A West Haven attorney leads the charge, and the lawsuit points to Ridgefield as the company’s U.S. headquarters—where, apparently, some big decisions about design and marketing happened.
Explore top-rated stays with no booking fees and instant confirmation. Your dream trip starts here!
Start Exploring Now
A Connecticut-led lawsuit targets Zantac cancer risk disclosures
The complaint puts Ridgefield, Connecticut, right in the spotlight. Plaintiffs claim Boehringer Ingelheim ignored ranitidine’s dangers even as Zantac’s sales soared past $1 billion a year.
People from several states are involved, including a man from Waterbury. They’re saying the company acted intentionally or at least recklessly with people’s lives. Craig Raabe, a West Haven attorney who knows his way around pharmaceutical lawsuits, brought the case on February 24.
The plaintiffs say everything from designing and testing the products to handling regulatory communications and marketing decisions happened at BI’s Ridgefield headquarters. That, they argue, makes Connecticut the right place for the lawsuit.
The players and venue: why Ridgefield and Waterbury matter
The complaint goes after Boehringer Ingelheim for allegedly putting profit before safety. With a Waterbury plaintiff named, the case shows how ranitidine lawsuits keep popping up across the country—but this one grounds itself in Connecticut because of BI’s presence there.
At the time of this report, BI hadn’t said anything publicly. Ridgefield headquarters didn’t offer a comment either. All of this fits into the bigger picture: a nationwide wave of Zantac lawsuits that followed the FDA’s 2020 recall, which flagged “unacceptable levels” of a likely human carcinogen in ranitidine products.
Background: Zantac, ranitidine and the FDA recall
The 2020 FDA recall changed everything, turning a civil issue into a major public-health debate. The regulator’s findings led to thousands of lawsuits, all claiming Zantac and generic ranitidine could form cancer-causing compounds over time and under certain conditions.
The Connecticut lawsuit brings this national controversy home to a local court. Supporters of the plaintiffs say companies like Boehringer Ingelheim should’ve done more to warn people, especially when there were hints of risk. Meanwhile, the defense keeps insisting there’s no solid scientific proof that Zantac causes cancer, a line BI has taken in similar cases.
BI’s legal history and broader context
Boehringer Ingelheim has dealt with plenty of big lawsuits and settlements in the last decade. The way health-care products are marketed and monitored has shifted partly because of cases like these.
Take BI’s $650 million Pradaxa settlement in 2014, or the $95 million Justice Department settlement in 2012 over off-label marketing. Critics and supporters both point to these outcomes as signs of the risks pharma companies face in the post-Zantac world.
BI often argues in other courts that scientific evidence doesn’t support a cancer link to Zantac. In 2025, a Chicago jury sided with BI in a prostate cancer case, and the company now uses that win to push back against broad claims about ranitidine and cancer.
Recent outcomes and the ongoing docket
The back-and-forth between the Connecticut class action and BI’s victories elsewhere shows just how unsettled this legal landscape is. Some juries have sided with BI, but plenty of plaintiffs are still pursuing claims in courts all over the country.
The Zantac docket isn’t going quiet any time soon.
What Connecticut residents should know: towns connected to the case
This case touches communities all over Connecticut—and even beyond. It’s got implications for patients, lawmakers, and the folks working at local health centers.
Some key Connecticut towns and cities tied to the Zantac and ranitidine story include:
- Ridgefield
- Waterbury
- West Haven
- Danbury
- Bridgeport
- New Haven
- Stamford
- Hartford
- Norwalk
- Greenwich
If you’re reading from anywhere in the state, you’ve probably noticed Ridgefield’s role, the FDA’s ongoing involvement, and BI’s stance in court. All of it keeps Connecticut right in the middle of a national debate over drug safety and what companies should have to tell us.
Reporter Rob Ryser covers Greater Danbury development for Hearst Connecticut Media Group. He published this article on April 10, 2026, giving a local angle to a much bigger legal and regulatory story.
Here is the source article for this story: Class action suit says CT-based Zantac maker turned ‘a blind eye’
Find available hotels and vacation homes instantly. No fees, best rates guaranteed!
Check Availability Now
Fairfield County
Hartford County
Litchfield County
Middlesex County
New Haven County
New London County
Tolland County
